Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 15, 2024

BUY
$5.95 - $15.79 $761 - $2,021
128 Added 5.74%
2,359 $37,000
Q3 2023

Nov 14, 2023

SELL
$7.22 - $10.05 $3,003 - $4,180
-416 Reduced 15.72%
2,231 $17,000
Q2 2023

Aug 14, 2023

BUY
$4.89 - $10.57 $3,393 - $7,335
694 Added 35.54%
2,647 $26,000
Q2 2022

Aug 22, 2022

SELL
$5.7 - $10.33 $15,087 - $27,343
-2,647 Reduced 57.54%
1,953 $11,000
Q1 2022

May 16, 2022

BUY
$4.41 - $22.5 $4,687 - $23,917
1,063 Added 30.05%
4,600 $32,000
Q4 2021

Feb 14, 2022

BUY
$21.07 - $34.98 $48,123 - $79,894
2,284 Added 182.28%
3,537 $81,000
Q3 2021

Nov 15, 2021

BUY
$24.85 - $40.25 $31,137 - $50,433
1,253 New
1,253 $37,000

Others Institutions Holding ICVX

About Icosavax, Inc.


  • Ticker ICVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,885,200
  • Description
  • Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...
More about ICVX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.